Compare COSM & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | IMMP |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | Greece | Australia |
| Employees | 163 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 31.5M |
| IPO Year | 2009 | 2012 |
| Metric | COSM | IMMP |
|---|---|---|
| Price | $0.34 | $3.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 303.6K |
| Earning Date | 11-16-2026 | 09-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $23.79 | N/A |
| Revenue Next Year | $58.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.16 | $0.26 |
| 52 Week High | $1.26 | $5.36 |
| Indicator | COSM | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 67.55 |
| Support Level | $0.27 | $2.65 |
| Resistance Level | $0.35 | $5.36 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 26.28 | 64.73 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.